Sign up
Quantellect · Congress · Trade Detail
CRYCryoLife, Inc. (CRY) [ST] F ILING S TaTUS : New S UbHoLdING o F : Morgan Stanley - Select UMa account # 1
DemocratHouse

Josh Gottheimer bought CryoLife, Inc. (CRY) [ST] F ILING S TaTUS : New S UbHoLdING o F : Morgan Stanley - Select UMa account # 1 (CRY)

Josh Gottheimer (D-NJ), a U.S. Representative, has disclosed 3 trades in CryoLife, Inc. (CRY) [ST] F ILING S TaTUS : New S UbHoLdING o F : Morgan Stanley - Select UMa account # 1 (CRY) since 2020, 2 purchases and 1 sale, worth an estimated $24K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).

The trade highlighted here is a purchase: Josh Gottheimer bought $1,001 - $15,000 of CryoLife, Inc. (CRY) [ST] F ILING S TaTUS : New S UbHoLdING o F : Morgan Stanley - Select UMa account # 1 (CRY) on January 14, 2020. Since that trade, CRY is down -24.69% against the S&P 500 up +147.86%, an outperformance of -172.55%.

Across these filings, Josh Gottheimer has been a net buyer of CRY (a buy-to-sell ratio of 2.00). The most recent disclosed CRY transaction shown was dated October 16, 2020. Each row in the table below links to that trade and its post-trade performance versus the market.

Data updated

CRY trades
3
Disclosed Vol
$24K
Buys
2
67%
Sells
1
33%
Buy / Sell
2.00
ratio
First → Last
2020

Josh Gottheimer's CRY trades vs the price

CRY is down -24.69% since Josh Gottheimer bought on January 14, 2020, versus +147.86% for the S&P 500.

Performance since this trade

Price change since trade
-24.69%
S&P 500 change since trade
+147.86%
Outperformance vs S&P 500
-172.55%

All Josh Gottheimer CRY trades

TradedTypeSizeReturnEst. profit
October 16, 2020BUY$1,001 - $15,000N/A
September 15, 2020SELL$1,001 - $15,000N/A
January 14, 2020BUY$1,001 - $15,000N/A

Estimated profit is shown for buys only, marked to the latest close. It is an estimate and does not net later sells, taxes, or fees.

Josh Gottheimer & CRY trading FAQ

Is it legal for Josh Gottheimer to trade CryoLife, Inc. (CRY) [ST] F ILING S TaTUS : New S UbHoLdING o F : Morgan Stanley - Select UMa account # 1 (CRY) stock?

Yes. Members of Congress are allowed to trade individual stocks, including CryoLife, Inc. (CRY) [ST] F ILING S TaTUS : New S UbHoLdING o F : Morgan Stanley - Select UMa account # 1 (CRY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.

When did Josh Gottheimer buy CRY?

Josh Gottheimer disclosed a purchase of $1,001 - $15,000 of CryoLife, Inc. (CRY) [ST] F ILING S TaTUS : New S UbHoLdING o F : Morgan Stanley - Select UMa account # 1 (CRY) on January 14, 2020, according to public STOCK Act filings.

How has CRY performed since Josh Gottheimer's trade?

Since Josh Gottheimer bought CRY on January 14, 2020, the stock is down -24.69%, versus +147.86% for the S&P 500 over the same period, an outperformance of -172.55%.

How many times has Josh Gottheimer traded CRY?

Josh Gottheimer has disclosed 3 CRY trades since 2020 (2 purchases and 1 sale). Every disclosed trade is listed on this page.

How soon must members of Congress disclose a trade?

Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.

Where can I see all congressional CRY trades?

Quantellect tracks every disclosed congressional trade in CryoLife, Inc. (CRY) [ST] F ILING S TaTUS : New S UbHoLdING o F : Morgan Stanley - Select UMa account # 1 (CRY) on the CryoLife, Inc. (CRY) [ST] F ILING S TaTUS : New S UbHoLdING o F : Morgan Stanley - Select UMa account # 1 congressional trading page, which aggregates filings across all members of Congress.

Josh Gottheimer's CRY tradesAll congressional filings for CryoLife, Inc. (CRY) [ST] F ILING S TaTUS : New S UbHoLdING o F : Morgan Stanley - Select UMa account # 1Josh Gottheimer's full profile

Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.